PE20010153A1 - Derivados de 4-fenil-pirimidina como antagonistas del receptor de neuroquinina - Google Patents
Derivados de 4-fenil-pirimidina como antagonistas del receptor de neuroquininaInfo
- Publication number
- PE20010153A1 PE20010153A1 PE2000000508A PE0005082000A PE20010153A1 PE 20010153 A1 PE20010153 A1 PE 20010153A1 PE 2000000508 A PE2000000508 A PE 2000000508A PE 0005082000 A PE0005082000 A PE 0005082000A PE 20010153 A1 PE20010153 A1 PE 20010153A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- alkyl
- methyl
- pyrimidine
- neuroquinin
- Prior art date
Links
- MKLQPIYLZMLAER-UHFFFAOYSA-N 4-phenylpyrimidine Chemical class C1=CC=CC=C1C1=CC=NC=N1 MKLQPIYLZMLAER-UHFFFAOYSA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- -1 AMINO, PHENYL Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- ADTNSTHKMIPKIJ-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)phenyl]-n-methylmethanamine Chemical compound CNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ADTNSTHKMIPKIJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical group F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A DERIVAADOS DE 4-FENIL-PIRIMIDINA DE FORMULA I, DONDE R1 ES H, HALOGENO; R2 ES H, HALOGENO, ALQUILO, ALCOXILO; R1 Y R2 JUNTO A C FORNAN -CH=CH-CH=CH-; R3 ES HALOGENO, TRIFLUOROMETILO, ALQUILO, ALCOXILO; R4 Y R4` SON H, ALQUILO; R5 ES ALQUILO, ALCOXILO, AMINO, FENILO, ENTRE OTROS; n ES 0-2; X ES -CON(R4")-, -NR4"CO-. SON COMPUESTOS PREFERIDOS ACIDO 4-(2-BROMO-FENIL)-2-(4-METIL-PIPERAZIN-1-IL)-PIRIMIDIN-5-CARBOXILICO (3,5-BISTRIFLUORO-METIL-BENCIL))-METIL-AMIDA, ACIDO 4-(2-CLORO-FENIL)-2-(2-DIMETILAMINO-ETIL-AMINO)-PIRIMIDIN-5-CARBOXILICO (3,5-BISTRIFLUOROMETIL-BENCIL)-METIL-AMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR DE LA NEUROQUININA NK-1 Y PUEDE SER UTIL PARA EL TRATAMIENTO DEL DOLOR, CEFALEA, MIGRANA, ENFERMEDAD DE ALZHEIMER, ANSIEDAD DEPRESION, PSICOSIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99110483 | 1999-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010153A1 true PE20010153A1 (es) | 2001-02-08 |
Family
ID=8238271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000508A PE20010153A1 (es) | 1999-05-31 | 2000-05-26 | Derivados de 4-fenil-pirimidina como antagonistas del receptor de neuroquinina |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US6274588B1 (es) |
| EP (1) | EP1187815B1 (es) |
| JP (1) | JP3590592B2 (es) |
| KR (1) | KR100440106B1 (es) |
| CN (1) | CN1166643C (es) |
| AR (1) | AR024146A1 (es) |
| AT (1) | ATE317389T1 (es) |
| AU (1) | AU770786B2 (es) |
| BR (1) | BR0011127A (es) |
| CA (1) | CA2375671C (es) |
| CO (1) | CO5170520A1 (es) |
| CZ (1) | CZ20014271A3 (es) |
| DE (1) | DE60025918T2 (es) |
| DK (1) | DK1187815T3 (es) |
| ES (1) | ES2257294T3 (es) |
| GC (1) | GC0000191A (es) |
| HK (1) | HK1046528B (es) |
| HR (1) | HRP20010871A2 (es) |
| HU (1) | HUP0201315A3 (es) |
| IL (2) | IL146460A0 (es) |
| JO (1) | JO2261B1 (es) |
| MA (1) | MA26793A1 (es) |
| MX (1) | MXPA01012089A (es) |
| MY (1) | MY122731A (es) |
| NO (1) | NO321354B1 (es) |
| NZ (1) | NZ515407A (es) |
| PE (1) | PE20010153A1 (es) |
| PL (1) | PL353441A1 (es) |
| PT (1) | PT1187815E (es) |
| RU (1) | RU2243221C2 (es) |
| SI (1) | SI1187815T1 (es) |
| TR (1) | TR200103457T2 (es) |
| TW (1) | TW550258B (es) |
| WO (1) | WO2000073279A1 (es) |
| YU (1) | YU84901A (es) |
| ZA (1) | ZA200109163B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| JP4623354B2 (ja) * | 2000-09-14 | 2011-02-02 | 味の素株式会社 | 新規ピリミジン誘導体及び新規ピリジン誘導体 |
| EP1361879A1 (en) * | 2001-02-20 | 2003-11-19 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
| GB0201882D0 (en) * | 2002-01-28 | 2002-03-13 | Novartis Ag | Organic compounds |
| EP1679309A4 (en) * | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
| HUP0400405A3 (en) * | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| WO2006050476A2 (en) * | 2004-11-03 | 2006-05-11 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as ion channel modulators and methods of use |
| CA2601935C (en) * | 2005-02-22 | 2013-04-09 | F. Hoffmann-La Roche Ag | Nk1 antagonists |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
| US8372849B2 (en) | 2008-04-21 | 2013-02-12 | Taigen Biotechnology Co., Ltd. | Heterocyclic compounds |
| US8580805B2 (en) * | 2010-08-31 | 2013-11-12 | Hubert Maehr | Pyrimidine carboxamide derivatives |
| BR112017016131A2 (pt) * | 2015-01-30 | 2018-04-17 | Basf Se | ?uso de fenilpiridinas, fenilpirimidinas, processos para preparação de fenilpirimidinas e para preparação de composições ativas herbicidas, pirimidinas, composição herbicida, e, método para controlar vegetação indesejada?. |
| WO2018132326A1 (en) * | 2017-01-10 | 2018-07-19 | National Health Research Institutes | Heterocyclic compounds and use thereof |
| KR102006547B1 (ko) | 2017-11-16 | 2019-08-01 | 서울대학교산학협력단 | 벤즈아미드 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 염증질환의 치료 또는 예방용 약학적 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940394A (en) * | 1972-03-31 | 1976-02-24 | Santilli Arthur A | 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides |
| AR208171A1 (es) * | 1972-09-29 | 1976-12-09 | Ciba Geigy Ag | Procedimiento para la obtencion de nuevos derivados del acido cef-3-em-4-carboxilico |
| US4698340A (en) | 1984-07-19 | 1987-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine derivatives, processes for preparation thereof and composition containing the same |
| DE3614060A1 (de) * | 1986-04-23 | 1987-10-29 | Schering Ag | Pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide |
| US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| WO1995018124A1 (en) | 1993-12-29 | 1995-07-06 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
| JPH11512399A (ja) | 1995-09-01 | 1999-10-26 | シグナル ファーマシューティカルズ，インコーポレイテッド | ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法 |
| US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
-
2000
- 2000-05-22 US US09/575,382 patent/US6274588B1/en not_active Expired - Fee Related
- 2000-05-22 TW TW089109829A patent/TW550258B/zh not_active IP Right Cessation
- 2000-05-24 PT PT00927234T patent/PT1187815E/pt unknown
- 2000-05-24 ES ES00927234T patent/ES2257294T3/es not_active Expired - Lifetime
- 2000-05-24 MX MXPA01012089A patent/MXPA01012089A/es active IP Right Grant
- 2000-05-24 BR BR0011127-9A patent/BR0011127A/pt not_active Application Discontinuation
- 2000-05-24 IL IL14646000A patent/IL146460A0/xx active IP Right Grant
- 2000-05-24 CN CNB008082758A patent/CN1166643C/zh not_active Expired - Fee Related
- 2000-05-24 NZ NZ515407A patent/NZ515407A/xx unknown
- 2000-05-24 JP JP2000621345A patent/JP3590592B2/ja not_active Expired - Fee Related
- 2000-05-24 YU YU84901A patent/YU84901A/sh unknown
- 2000-05-24 TR TR2001/03457T patent/TR200103457T2/xx unknown
- 2000-05-24 HK HK02107643.4A patent/HK1046528B/zh not_active IP Right Cessation
- 2000-05-24 DE DE60025918T patent/DE60025918T2/de not_active Expired - Fee Related
- 2000-05-24 PL PL00353441A patent/PL353441A1/xx unknown
- 2000-05-24 KR KR10-2001-7015393A patent/KR100440106B1/ko not_active Expired - Fee Related
- 2000-05-24 CZ CZ20014271A patent/CZ20014271A3/cs unknown
- 2000-05-24 EP EP00927234A patent/EP1187815B1/en not_active Expired - Lifetime
- 2000-05-24 HR HR20010871A patent/HRP20010871A2/hr not_active Application Discontinuation
- 2000-05-24 DK DK00927234T patent/DK1187815T3/da active
- 2000-05-24 SI SI200030813T patent/SI1187815T1/sl unknown
- 2000-05-24 WO PCT/EP2000/004701 patent/WO2000073279A1/en not_active Ceased
- 2000-05-24 CA CA002375671A patent/CA2375671C/en not_active Expired - Fee Related
- 2000-05-24 AU AU45677/00A patent/AU770786B2/en not_active Ceased
- 2000-05-24 RU RU2001133458/04A patent/RU2243221C2/ru not_active IP Right Cessation
- 2000-05-24 AT AT00927234T patent/ATE317389T1/de not_active IP Right Cessation
- 2000-05-24 HU HU0201315A patent/HUP0201315A3/hu unknown
- 2000-05-26 PE PE2000000508A patent/PE20010153A1/es not_active Application Discontinuation
- 2000-05-28 JO JO200083A patent/JO2261B1/en active
- 2000-05-29 AR ARP000102643A patent/AR024146A1/es not_active Application Discontinuation
- 2000-05-29 MY MYPI20002384A patent/MY122731A/en unknown
- 2000-05-29 CO CO00039590A patent/CO5170520A1/es not_active Application Discontinuation
- 2000-05-30 GC GCP2000684 patent/GC0000191A/en active
-
2001
- 2001-11-06 ZA ZA200109163A patent/ZA200109163B/en unknown
- 2001-11-12 IL IL146460A patent/IL146460A/en not_active IP Right Cessation
- 2001-11-22 NO NO20015700A patent/NO321354B1/no unknown
- 2001-11-26 MA MA26424A patent/MA26793A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010153A1 (es) | Derivados de 4-fenil-pirimidina como antagonistas del receptor de neuroquinina | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| RU2328494C2 (ru) | Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло[2.2.1]гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина | |
| PE20010039A1 (es) | Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato | |
| PE20030238A1 (es) | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales | |
| PE20001088A1 (es) | Compuestos derivados de tetrahidrobenzazepina | |
| EA200400830A1 (ru) | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ОТНОСЯЩИЕСЯ К A2b-СЕЛЕКТИВНЫМ АНТАГОНИСТАМ, ИХ СИНТЕЗ И ПРИМЕНЕНИЕ | |
| PE20021072A1 (es) | DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2 | |
| PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| PE20020506A1 (es) | Derivados de pirazol fusionados como inhibidores de la proteina cinasa | |
| PE20050132A1 (es) | Piperazinas heterociclicas sustituidas | |
| PE20011114A1 (es) | Decahidro-isoquinolinas | |
| PE20010219A1 (es) | AGONISTAS ß-ADRENORRECEPTORES | |
| JP2005509622A5 (es) | ||
| PE20020258A1 (es) | Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1) | |
| TR200401546T4 (tr) | Piperazin türevleri, hazırlanmaları ve merkezi sinir sistemi (CNS) bozukluklarının tedavisinde kullanımları | |
| PE20030541A1 (es) | Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13 | |
| PE20020665A1 (es) | ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3 | |
| PE20080345A1 (es) | Derivados de piperazina como agonistas del receptor de gpr38 | |
| PE20021158A1 (es) | Derivados de sulfonamida como antagonistas del receptor de bradiquinina | |
| PE75199A1 (es) | Derivado de quinolina util como antagonista de neuroquinina | |
| PE20071224A1 (es) | Derivados de aminometilpiridina como antagonistas de los receptores cannabinoides 1 (cb1) | |
| PE20001549A1 (es) | Derivados de bifenilo como antagonistas del receptor de neuroquinina 1 | |
| PE20020407A1 (es) | Derivados de quinazolina como antagonistas del receptor adrenergico alfa-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |